RELiZORB Pediatric Registry
Observational data collection in pediatric GI patients
RegistryActive
Key Facts
Indication
Observational data collection in pediatric GI patients
Phase
Registry
Status
Active
Company
About Alcresta Therapeutics
Alcresta Therapeutics is a commercial-stage biotech company addressing a critical unmet need in enteral nutrition for patients with rare diseases. Its core technology is the RELiZORB cartridge, which contains immobilized lipase (iLipase) to break down fats in tube feeding formulas, mimicking pancreatic function. The company has achieved FDA clearance for expanded use in neonates and infants and is generating real-world evidence to support its product. Led by an experienced management team, Alcresta is positioned in the niche but essential markets of metabolic and rare diseases with a specialized drug delivery platform.
View full company profile